-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration

Sponsor: educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events
Friday, December 8, 2023: 11:00 AM-2:00 PM
Room 30 A-E (San Diego Convention Center)
Sikander Ailawadhi, Mayo Clinic and Ajai Chari, MD, University of California, San Francisco
Ailawadhi: AbbVie, Amgen, Ascentage, BMS, Cellectar, GSK, Janssen, Pharmacyclics, Sanofi: Research Funding; Beigene, BMS, Cellectar, GSK, Janssen, Pfizer, Regeneron, Sanofi, Takeda: Consultancy.
On Demand program will be available here December 29, 2023.

The evolution of CAR-T therapies – where do we stand now with this revolutionary treatment approach?

Join our faculty experts for this 1-hour accredited event about the current role of CAR T-cell therapies in management of patients with relapsed/refractory multiple myeloma (RRMM). Dr. Ajai Chari and Dr. Sikander Ailawadhi will discuss and debate practical challenges such as: Is prior treatment sequencing a significant factor in patient response to CAR T-cell therapy? Should all eligible patients with RRMM receive CAR T-cell therapy, or is fitness/frailty a concern? How can we prevent, identify, and manage adverse events? When is treatment discontinuation the best choice? What administration and cost issues need to be considered? And more...

Bring your hard-hitting questions - attendees can challenge the faculty through our interactive Q&A, and the faculty will challenge you back with a series of interactive, case scenarios.